Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes

Inclusion Criteria: I1. Fasting glycemia \> 6,1 mmol/L. (1,1 g/L). I2. 2 hours glycemia (OGTT) \> 7,8 mmol/L (1,4 g/L). I3. HbA1c \< 7% I4. Triglyceridemia \> 1,5 g/L. I5. Prediabetic or type-2 diabetic but not requiring immediate drug therapy according to the current recommendations (HAS, 2013). I6. Waist circumference \> 94 cm for men or \> 80 cm for women. I7. With reported body weight variation \< 5% in the 3 months prior the randomization. I8. Without significant change in food habits or in physical activity in the 3 months before randomization and agreeing to keep them unchanged throughout the study (no hyper-hypocaloric diet nor start-stop of sport activity planned in the next 7 months). I9. For women: Non menopausal with the same reliable contraception since at least three months before the beginning of the study and agreeing to keep it during the entire duration of the study (hormonal contraception, intra uterine device or surgical intervention) or menopausal with or without hormone replacement therapy (oestrogenic replacement therapy begun from less than 3 months excluded). I10. Good general and mental health with in the opinion of the investigator: no clinically significant and relevant abnormalities of medical history or physical examination. I11. Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form. I12. Affiliated with a social security scheme. I13. Agree to be re…